ScholarLens Back to search
2014•Pediatric RheumatologyOpen access

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab

Fabrizio De Benedetti, Rayfel Schneider, Sheila S Weitzman, Clare E. Devlin, Kaori Daimaru, Shumpei Yokota, Syuji Takei, Angelo Ravelli

Open full text 7 citations

Abstract

Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Changes in therapies, including biologics, have been associated with the onset of MAS. Interleukin-6 (IL-6) plays a major pathogenic role in sJIA; data in animals suggest that high IL-6 levels contribute to the triggering of MAS [ 1 ]. Treatment with the IL-6 receptor inhibitor tocilizumab (TCZ) is highly effective in patients with sJIA [ 2 ].

Open-access reader

About this research paper

What this paper is about

Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Changes in therapies, including biologics, have been associated with the onset of MAS. Interleukin-6 (IL-6) plays a major pathogenic role in sJIA; data in animals suggest that high IL-6 levels contribute to the triggering of MAS [ 1 ]. Treatment with the IL-6 receptor inhibitor tocilizumab (TCZ) is highly effective in patients with sJIA [ 2 ].

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of systemic juvenile idiopathic arthritis (sJIA). Changes in therapies, including biologics, have been associated with the onset of MAS. Interleukin-6 (IL-6) plays a major pathogenic role in sJIA; data in animals suggest that high IL-6 levels contribute to the triggering of MAS [ 1 ]. Treatment with the IL-6 receptor inhibitor tocilizumab (TCZ) is highly effective in patients with sJIA [ 2 ].

Key concepts: Tocilizumab, Macrophage activation syndrome, Medicine, Rheumatology, Arthritis, Juvenile, Interleukin 6, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab — Research Paper | ScholarLens